Definium Therapeutics, Inc. (DFTX)

NASDAQ: DFTX · USD

$38.1

+1.03 (+2.8%)· Recorded snapshot

Market cap	5.1B
Net income (ttm)	-353.8M
EPS (ttm)	-$3.48
Shares out	134.4M
Volume	1,421,244
Beta	2.19

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -353.8M
EPS (ttm): -$3.48
Market cap: 5.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-64.1

P25 -113.8P50 -46.5P75 -0.9

ROIC-24.1

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All DFTX indicators

Market & fundamental data

Available fields

173

Groups with data

Currency

USD

Showing 173 of 173 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001813814
Company name	Definium Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	24477V105
Earnings date	2026-11-09
Earnings time	amc
Employees	106
Employees change	32
Employees growth	43.24%
Enterprise value	$4.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	CA24477V1058
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2022-08-29
Last stock split type	Reverse
Market cap	$5.1B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$38.11
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	DFTX
U.S. state	New York
Website	https://definiumtx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-9.14%
FCF / EV yield	-4.13%
FCF yield	-3.29%
P/B ratio	5.42x
Price / tangible book value	5.69x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-3.3M
ROA	-20.64%
ROA (5Y)	-34.15%
ROCE	-23.81%
ROE	-64.09%
ROE (5Y)	-67%
ROIC	-24.06%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-227.5M
EPS	$-3.48
FCF per share	$-1.25
Financing cash flow	$1B
Free cash flow	$-168M
Free cash flow minus SBC	$-203.7M
Investing cash flow	$-224.3M
Net cash flow	$621.9M
Net income	$-353.8M
Operating cash flow minus SBC	$-203.7M
Operating income	$-227.5M
Stock-based compensation	$35.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$6.84
Debt / equity	0.04
Goodwill	$19.9M
Interest coverage	-45.33
Long-term assets	$20.8M
Long-term liabilities	$37M
Net cash (debt)	$1B
Net cash / market cap	20.5%
Net cash growth	641.78%
Net debt / equity	-1.14
Piotroski F-Score	3
Shareholders' equity	$918.7M
Tangible book value	$898.8M
Tangible book value per share	$6.69
Total assets	$1.1B
Total cash	$1.1B
Total debt	$36.5M
Total liabilities	$194.2M
WACC	16.28%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$1.1B
Current liabilities	$157.2M
Current ratio	6.95
Net working capital	$-149M
Quick ratio	6.89
Working capital	$934.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-22.22%
Dividend yield	0%
Shareholder yield	-22.22%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$33.41
1D price change	2.78%
1M price change	5.36%
1M total return	5.36%
1W price change	7.38%
1W total return	7.38%
1Y price change	197.04%
1Y return CAGR	197.26%
1Y total return	197.04%
20-day SMA	$35.47
200-day SMA	$29.38
3M price change	-10.64%
3M total return	-10.64%
3Y price change	1,442.92%
3Y return CAGR	148.9%
3Y total return	1,442.92%
50-day SMA	$38.11
50-day SMA vs 200-day SMA	50over200
52-week high	$49.70
52-week high date	2026-08-07
52-week low	$10.47
52-week low date	2025-11-21
5Y price change	12.42%
5Y return CAGR	2.37%
5Y total return	12.42%
6M price change	81.65%
6M total return	81.65%
All-time high	$86.55
All-time high date	2021-04-27
All-time low	$1.25
All-time low date	2020-03-06
Average true range (ATR)	$1.80
Average volume	1.9M
Beta (1Y)	0.54
Beta (2Y)	1.48
Beta (5Y)	2.19
Change from 52-week high	-23.32%
Change from 52-week low	264.17%
Change from all-time high	-55.97%
Change from all-time low	2,951.24%
Change from open	3.67%
Day's gap	-0.86%
Dollar volume	$54.2M
High price	$38.34
Low price	$36.76
Monthly RSI	72.3
Open price	$36.76
Position in 52-week range	85.44%
Premarket change	0.73%
Premarket close	$37.08
Premarket price	$37.35
Premarket volume	2.2K
Previous close	$37.08
Price vs 150-day SMA	14.06%
Price vs 20-day SMA	7.46%
Price vs 200-day SMA	29.71%
Price vs 50-day SMA	0.01%
Relative volume	0.73
RSI	57.2
Sharpe ratio	1.71
Sharpe ratio (3Y)	1.41
Sharpe ratio (5Y)	0.39
Sortino ratio	3.64
Sortino ratio (3Y)	2.66
Sortino ratio (5Y)	0.7
Volume	1.4M
Weekly RSI	57.1
YTD price change	184.62%
YTD total return	184.62%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	125.5M
Float percentage	93.42%
Shares change (QoQ)	1.74%
Shares change (YoY)	22.22%
Shares held by insiders	1.23%
Shares held by institutions	81.83%
Shares outstanding	134.4M
Short % of float	8%
Short % of shares	7.48%
Short ratio	4.8 days

Deeper analysis on DFTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DFTX report

Is a complete DFTX research report available?

No complete published report is available for Definium Therapeutics, Inc. (DFTX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Definium Therapeutics, Inc. (DFTX)

Price

Financial snapshot

Fair-value bridge

Latest news · DFTX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DFTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DFTX

Frequently asked questions